Gene therapy is transitioning from experimental promise to clinical reality in 2026, with recent trial results demonstrating measurable therapeutic outcomes in previously untreatable genetic diseases. The field has reached an inflection point where specific interventions are producing reproducible clinical benefits, regulatory pathways are becoming clearer, and the technical barriers that limited early applications are yielding to refined delivery systems and improved vector designs. For researchers and healthcare professionals tracking therapeutic development, the current landscape demands attention not to distant possibilities but to …









